MICHAELA SULLIVAN: Open Payments
NPI 1982308193 · LOVELAND, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,619 in 62 payments from 19 companies in 2025. Trend: 2023 $1,057 · 2024 $2,933 · 2025 $1,619
Food & beverage: $1,619
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 6 | $271 |
| ABBVIE INC. | 9 | $269 |
| Novartis Pharmaceuticals Corporation | 12 | $172 |
| Amgen Inc. | 1 | $125 |
| GENZYME CORPORATION | 4 | $119 |
| Galderma Laboratories, L.P. | 5 | $88 |
| Lilly USA, LLC | 3 | $82 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | 3 | $68 |
| Incyte Corporation | 3 | $64 |
| E.R. Squibb & Sons, L.L.C. | 3 | $63 |
Products named: Bimzelx, SKYRIZI, DUPIXENT, COSENTYX, OTEZLA, RINVOQ, NEMLUVIO, OPZELURA.
Industry payments across CO — which companies pay providers there.
